BIOMAT Database Logo BIOMAT Database Logo

Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors. 1992

M B Vasudevachari, and C Battista, and H C Lane, and M C Psallidopoulos, and B Zhao, and J Cook, and J R Palmer, and D L Romero, and W G Tarpley, and N P Salzman
Department of Microbiology, Georgetown University Medical Center, Washington, DC 20007.

Certain bisheteroarylpiperazines (BHAPs) directly inhibit the replication of human immunodeficiency virus type 1 (HIV-1) and block the spread of infection to susceptible populations of cells. At a 1 microM concentration three analogs, U-87201, U-88204, and U-89674, inhibited the replication of HIV-1 in MT-2 cells by 83, 100, and 93%, respectively. At the same concentration, U-88204 completely inhibited replication of primary HIV-1 isolates in peripheral blood mononuclear cells. Replication of 3'-azido-2',3'-dideoxythymidine (AZT)-resistant strains of HIV-1 was also inhibited by U-88204. When MT-2 cells that were lytically infected with HIV-1 were mixed with uninfected MT-2 cells, U-88204 provided complete protection to the uninfected cells. Integrated proviral DNA sequences were not detected by the polymerase chain reaction technique in this culture after 15 days in the presence of drug. The resultant healthy cell culture was subsequently maintained without drug with no evidence of latent proviral DNA. Serial passage of a laboratory strain and a primary isolate of HIV-1 in cell culture in the presence of increasing concentrations of U-88204 yielded virus populations which were at least 100-fold resistant to the drug. These resistant viruses also showed cross-resistance to the pyridinone class of nonnucleoside inhibitors but were sensitive to AZT. Analysis of the nucleotide sequence of resistant viruses revealed mutations at conserved regions of the reverse transcriptase (RT) gene. The results presented here suggest the therapeutic potential of U-88204 in the combination therapy for HIV-1 infection.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014764 Viral Proteins Proteins found in any species of virus. Gene Products, Viral,Viral Gene Products,Viral Gene Proteins,Viral Protein,Protein, Viral,Proteins, Viral
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse

Related Publications

M B Vasudevachari, and C Battista, and H C Lane, and M C Psallidopoulos, and B Zhao, and J Cook, and J R Palmer, and D L Romero, and W G Tarpley, and N P Salzman
HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors.
January 1996, Biochemistry,
M B Vasudevachari, and C Battista, and H C Lane, and M C Psallidopoulos, and B Zhao, and J Cook, and J R Palmer, and D L Romero, and W G Tarpley, and N P Salzman
Development of nonnucleoside HIV reverse transcriptase inhibitors.
January 1996, Methods in enzymology,
M B Vasudevachari, and C Battista, and H C Lane, and M C Psallidopoulos, and B Zhao, and J Cook, and J R Palmer, and D L Romero, and W G Tarpley, and N P Salzman
Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol.
November 2006, PLoS pathogens,
M B Vasudevachari, and C Battista, and H C Lane, and M C Psallidopoulos, and B Zhao, and J Cook, and J R Palmer, and D L Romero, and W G Tarpley, and N P Salzman
Developing novel nonnucleoside HIV-1 reverse transcriptase inhibitors: beyond the butterfly.
January 2006, Current pharmaceutical design,
M B Vasudevachari, and C Battista, and H C Lane, and M C Psallidopoulos, and B Zhao, and J Cook, and J R Palmer, and D L Romero, and W G Tarpley, and N P Salzman
Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase.
June 2001, Proceedings of the National Academy of Sciences of the United States of America,
M B Vasudevachari, and C Battista, and H C Lane, and M C Psallidopoulos, and B Zhao, and J Cook, and J R Palmer, and D L Romero, and W G Tarpley, and N P Salzman
Nonnucleoside reverse transcriptase inhibitors.
October 1997, AIDS clinical care,
M B Vasudevachari, and C Battista, and H C Lane, and M C Psallidopoulos, and B Zhao, and J Cook, and J R Palmer, and D L Romero, and W G Tarpley, and N P Salzman
Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.
October 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
M B Vasudevachari, and C Battista, and H C Lane, and M C Psallidopoulos, and B Zhao, and J Cook, and J R Palmer, and D L Romero, and W G Tarpley, and N P Salzman
Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.
February 1995, Science (New York, N.Y.),
M B Vasudevachari, and C Battista, and H C Lane, and M C Psallidopoulos, and B Zhao, and J Cook, and J R Palmer, and D L Romero, and W G Tarpley, and N P Salzman
New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
June 2009, Journal of medicinal chemistry,
M B Vasudevachari, and C Battista, and H C Lane, and M C Psallidopoulos, and B Zhao, and J Cook, and J R Palmer, and D L Romero, and W G Tarpley, and N P Salzman
N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
March 2013, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!